These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Therapeutic potential of triheptanoin in metabolic and neurodegenerative diseases. Wehbe Z; Tucci S J Inherit Metab Dis; 2020 May; 43(3):385-391. PubMed ID: 31778232 [TBL] [Abstract][Full Text] [Related]
23. Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement. Pascual JM; Liu P; Mao D; Kelly DI; Hernandez A; Sheng M; Good LB; Ma Q; Marin-Valencia I; Zhang X; Park JY; Hynan LS; Stavinoha P; Roe CR; Lu H JAMA Neurol; 2014 Oct; 71(10):1255-65. PubMed ID: 25110966 [TBL] [Abstract][Full Text] [Related]
24. Mice carrying the szt1 mutation exhibit increased seizure susceptibility and altered sensitivity to compounds acting at the m-channel. Otto JF; Yang Y; Frankel WN; Wilcox KS; White HS Epilepsia; 2004 Sep; 45(9):1009-16. PubMed ID: 15329063 [TBL] [Abstract][Full Text] [Related]
25. Randomized trial of add-on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy. Borges K; Kaul N; Germaine J; Kwan P; O'Brien TJ Epilepsia Open; 2019 Mar; 4(1):153-163. PubMed ID: 30868125 [TBL] [Abstract][Full Text] [Related]
26. Genetic animal models of epilepsy as a unique resource for the evaluation of anticonvulsant drugs. A review. Löscher W Methods Find Exp Clin Pharmacol; 1984 Sep; 6(9):531-47. PubMed ID: 6439966 [TBL] [Abstract][Full Text] [Related]
27. [GABAergic mechanisms in generalized epilepsies: the neuroanatomical dimension]. Depaulis A; Deransart C; Vergnes M; Marescaux C Rev Neurol (Paris); 1997; 153 Suppl 1():S8-13. PubMed ID: 9686242 [TBL] [Abstract][Full Text] [Related]
29. Video-EEG evidence of lateralized clinical features in primary generalized epilepsy with tonic-clonic seizures. Casaubon L; Pohlmann-Eden B; Khosravani H; Carlen PL; Wennberg R Epileptic Disord; 2003 Sep; 5(3):149-56. PubMed ID: 14684350 [TBL] [Abstract][Full Text] [Related]
30. Triheptanoin for the treatment of brain energy deficit: A 14-year experience. Mochel F J Neurosci Res; 2017 Nov; 95(11):2236-2243. PubMed ID: 28688166 [TBL] [Abstract][Full Text] [Related]
31. A triheptanoin-supplemented diet rescues hippocampal hyperexcitability and seizure susceptibility in FoxG1 Testa G; Mainardi M; Olimpico F; Pancrazi L; Cattaneo A; Caleo M; Costa M Neuropharmacology; 2019 Apr; 148():305-310. PubMed ID: 30639390 [TBL] [Abstract][Full Text] [Related]
32. Absence seizures in succinic semialdehyde dehydrogenase deficient mice: a model of juvenile absence epilepsy. Cortez MA; Wu Y; Gibson KM; Snead OC Pharmacol Biochem Behav; 2004 Nov; 79(3):547-53. PubMed ID: 15582027 [TBL] [Abstract][Full Text] [Related]
34. Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures. Löscher W; Potschka H; Rieck S; Tipold A; Rundfeldt C Epilepsia; 2004 Oct; 45(10):1228-39. PubMed ID: 15461677 [TBL] [Abstract][Full Text] [Related]
35. Multiple molecular mechanisms for a single GABAA mutation in epilepsy. Reid CA; Kim T; Phillips AM; Low J; Berkovic SF; Luscher B; Petrou S Neurology; 2013 Mar; 80(11):1003-8. PubMed ID: 23408872 [TBL] [Abstract][Full Text] [Related]
36. Differential effects of low glucose concentrations on seizures and epileptiform activity in vivo and in vitro. Kirchner A; Velísková J; Velísek L Eur J Neurosci; 2006 Mar; 23(6):1512-22. PubMed ID: 16553614 [TBL] [Abstract][Full Text] [Related]
37. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs. Ji-qun C; Ishihara K; Nagayama T; Serikawa T; Sasa M Epilepsia; 2005 Sep; 46(9):1362-70. PubMed ID: 16146430 [TBL] [Abstract][Full Text] [Related]
38. Effects of 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3.2-e]-1,3-thiazin-4-one (YM928), an orally active alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, in models of generalized epileptic seizure in mice and rats. Yamashita H; Ohno K; Amada Y; Hattori H; Ozawa-Funatsu Y; Toya T; Inami H; Shishikura J; Sakamoto S; Okada M; Yamaguchi T J Pharmacol Exp Ther; 2004 Jan; 308(1):127-33. PubMed ID: 14569061 [TBL] [Abstract][Full Text] [Related]
39. Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy. Russo E; Constanti A; Ferreri G; Citraro R; De Sarro G Neuropharmacology; 2004 May; 46(6):865-78. PubMed ID: 15033346 [TBL] [Abstract][Full Text] [Related]
40. Hippocampal volume and cell density changes in a mouse model of human genetic epilepsy. Richards KL; Kurniawan ND; Yang Z; Kim TH; Keller MD; Low J; Ullmann JF; Cole S; Foong S; Galloway GJ; Reid CA; Paxinos G; Reutens DC; Petrou S Neurology; 2013 Mar; 80(13):1240-6. PubMed ID: 23468543 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]